

Andrea Calvo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1556482/publications.pdf>

Version: 2024-02-01

177
papers

12,613
citations

31976

53
h-index

29157

104
g-index

187
all docs

187
docs citations

187
times ranked

12418
citing authors

#	ARTICLE	IF	CITATIONS
1	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. <i>Neuron</i> , 2010, 68, 857-864.	8.1	1,100
2	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. <i>Lancet Neurology</i> , The, 2012, 11, 323-330.	10.2	1,039
3	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. <i>Neuron</i> , 2018, 97, 1268-1283.e6.	8.1	517
4	Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 740-746.	1.9	513
5	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2016, 48, 1043-1048.	21.4	494
6	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. <i>Nature Neuroscience</i> , 2014, 17, 664-666.	14.8	398
7	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. <i>Lancet Neurology</i> , The, 2018, 17, 423-433.	10.2	342
8	Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. <i>Lancet Neurology</i> , The, 2014, 13, 1108-1113.	10.2	302
9	Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. <i>Nature Communications</i> , 2016, 7, 12408.	12.8	290
10	<i>SQSTM1</i> mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. <i>Neurology</i> , 2012, 79, 1556-1562.	1.1	252
11	Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 168-173.	1.9	233
12	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <i>Nature Genetics</i> , 2021, 53, 1636-1648.	21.4	223
13	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2016, 48, 1037-1042.	21.4	218
14	Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. <i>Lancet Neurology</i> , The, 2014, 13, 1228-1240.	10.2	201
15	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	21.4	198
16	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. <i>Brain</i> , 2012, 135, 784-793.	7.6	182
17	Quadruplex-binding small molecules ameliorate <i>C9orf72</i> FTD / ALS pathology <i>in vitro</i> and <i>in vivo</i> . <i>EMBO Molecular Medicine</i> , 2018, 10, 22-31.	6.9	178
18	Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. <i>Neurology</i> , 2014, 83, 1067-1074.	1.1	154

#	ARTICLE	IF	CITATIONS
19	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1407-1416.	0.8	152
20	Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and Creatinine. <i>JAMA Neurology</i> , 2014, 71, 1134.	9.0	150
21	Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 251-259.	6.4	148
22	The multistep hypothesis of ALS revisited. <i>Neurology</i> , 2018, 91, e635-e642.	1.1	146
23	Extensive genetics of ALS. <i>Neurology</i> , 2012, 79, 1983-1989.	1.1	145
24	ALS in Italian professional soccer players: The risk is still present and could be soccer-specific. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 205-209.	2.1	144
25	Mice with endogenous <i>TDP-43</i> mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. <i>EMBO Journal</i> , 2018, 37, .	7.8	129
26	Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation. <i>Neurobiology of Aging</i> , 2009, 30, 1272-1275.	3.1	128
27	Pathogenic VCP Mutations Induce Mitochondrial Uncoupling and Reduced ATP Levels. <i>Neuron</i> , 2013, 78, 57-64.	8.1	127
28	ALS mutant FUS proteins are recruited into stress granules in induced Pluripotent Stem Cells (iPSCs) derived motoneurons. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 755-66.	2.4	121
29	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2019, 85, 470-481.	5.3	118
30	Cognitive impairment across ALS clinical stages in a population-based cohort. <i>Neurology</i> , 2019, 93, e984-e994.	1.1	115
31	In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2646-2653.	3.8	108
32	A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2009, 18, 1524-1532.	2.9	106
33	Large Proportion of Amyotrophic Lateral Sclerosis Cases in Sardinia Due to a Single Founder Mutation of the TARDBP Gene. <i>Archives of Neurology</i> , 2011, 68, 594.	4.5	104
34	The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 844-852.	6.4	103
35	Genetic counselling in ALS: facts, uncertainties and clinical suggestions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 478-485.	1.9	99
36	ALS phenotype is influenced by age, sex, and genetics. <i>Neurology</i> , 2020, 94, e802-e810.	1.1	99

#	ARTICLE	IF	CITATIONS
37	Factors predicting survival in ALS: a multicenter Italian study. <i>Journal of Neurology</i> , 2017, 264, 54-63.	3.6	96
38	Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2012, 33, 2231.e1-2231.e6.	3.1	86
39	Secular Trends of Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2017, 74, 1097.	9.0	85
40	¹⁸ F-FDG-PET correlates of cognitive impairment in ALS. <i>Neurology</i> , 2016, 86, 44-49.	1.1	84
41	FUS mutations in sporadic amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2011, 32, 550.e1-550.e4.	3.1	79
42	Physical activity and amyotrophic lateral sclerosis: A European population-based case-control study. <i>Annals of Neurology</i> , 2014, 75, 708-716.	5.3	79
43	Coagulation Failure in Patients With Acute-Chronic Liver Failure and Decompensated Cirrhosis: Beyond the International Normalized Ratio. <i>Hepatology</i> , 2018, 68, 2325-2337.	7.3	79
44	C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. <i>Neurobiology of Aging</i> , 2012, 33, 1848.e15-1848.e20.	3.1	76
45	Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. <i>Human Brain Mapping</i> , 2014, 35, 1710-1722.	3.6	76
46	Non-invasive ventilation in amyotrophic lateral sclerosis: a 10 year population based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 377-381.	1.9	73
47	Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 666-673.	1.9	73
48	Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study. <i>Muscle and Nerve</i> , 2011, 43, 189-195.	2.2	64
49	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2019, 18, 155-164.	10.2	63
50	Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute-Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival. <i>Hepatology</i> , 2020, 71, 1381-1390.	7.3	63
51	Genetic architecture of ALS in Sardinia. <i>Neurobiology of Aging</i> , 2014, 35, 2882.e7-2882.e12.	3.1	60
52	UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. <i>Neurobiology of Aging</i> , 2013, 34, 357.e1-357.e5.	3.1	59
53	A de novo missense mutation of the FUS gene in a sporadic ALS case. <i>Neurobiology of Aging</i> , 2011, 32, 553.e23-553.e26.	3.1	58
54	ALS/FTD phenotype in two Sardinian families carrying both C9ORF72 and TARDBP mutations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 730-733.	1.9	57

#	ARTICLE	IF	CITATIONS
55	Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. <i>Acta Neuropathologica</i> , 2011, 121, 611-622.	7.7	56
56	TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. <i>Brain Communications</i> , 2020, 2, fcaa142.	3.3	55
57	Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onset. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 98-105.	1.7	54
58	Amyotrophic Lateral Sclerosisâ€“Frontotemporal Lobar Dementia in 3 Families With p.Ala382Thr TARDBP Mutations. <i>Archives of Neurology</i> , 2010, 67, 1002-9.	4.5	53
59	<i>ATXN2</i> polyQ intermediate repeats are a modifier of ALS survival. <i>Neurology</i> , 2015, 84, 251-258.	1.1	52
60	Validity of hospital morbidity records for amyotrophic lateral sclerosis. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 723-727.	5.0	46
61	Association of Variants in the <i>SPTLC1</i> Gene With Juvenile Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 1236.	9.0	46
62	CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients. <i>Neurobiology of Aging</i> , 2015, 36, 1767.e3-1767.e6.	3.1	44
63	A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD. <i>Neurobiology of Aging</i> , 2011, 32, 2327.e1-2327.e5.	3.1	43
64	Resting state functional connectivity alterations in primary lateral sclerosis. <i>Neurobiology of Aging</i> , 2014, 35, 916-925.	3.1	41
65	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. <i>Neurobiology of Aging</i> , 2016, 43, 180.e1-180.e5.	3.1	40
66	Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis. <i>Human Brain Mapping</i> , 2016, 37, 942-953.	3.6	40
67	Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 373-379.	1.7	40
68	The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonisms. <i>Neurogenetics</i> , 2013, 14, 161-166.	1.4	38
69	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. <i>Science Translational Medicine</i> , 2022, 14, eabj0264.	12.4	38
70	Amyotrophic lateral sclerosis/frontotemporal dementia with predominant manifestations of obsessiveâ€“compulsive disorder associated to GGGGCC expansion of the c9orf72 gene. <i>Journal of Neurology</i> , 2012, 259, 2723-2725.	3.6	37
71	Influence of cigarette smoking on ALS outcome: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1229-1233.	1.9	37
72	The Role of<i>APOE</i> in the Occurrence of Frontotemporal Dementia in Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 425.	9.0	37

#	ARTICLE	IF	CITATIONS
73	The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2020, 267, 3258-3267.	3.6	37
74	NADPH oxidase (NOX2) activity is a modifier of survival in ALS. <i>Journal of Neurology</i> , 2014, 261, 2178-2183.	3.6	36
75	Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. <i>Frontiers in Neuroscience</i> , 2019, 13, 485.	2.8	35
76	C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 281.1-281.	1.9	33
77	Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. <i>Brain</i> , 2018, 141, 2272-2279.	7.6	33
78	Eye Tracking Impact on Quality-of-Life of ALS Patients. <i>Lecture Notes in Computer Science</i> , 2008, , 70-77.	1.3	32
79	The last months of life of people with amyotrophic lateral sclerosis in mechanical invasive ventilation: A qualitative study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 499-504.	1.7	31
80	Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 99.	2.9	30
81	Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12335-12338.	7.1	29
82	Amyotrophic lateral sclerosis among the migrant population to Piemonte, northwestern Italy. <i>Journal of Neurology</i> , 1999, 246, 175-180.	3.6	28
83	A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2061-2071.	6.4	27
84	Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 590-597.	1.7	27
85	Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 308-311.	1.7	27
86	Cognitive screening in patients with amyotrophic lateral sclerosis in early stages. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 95-101.	2.1	26
87	Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 118-125.	1.7	26
88	Neuropathology of Olfactory Ensheathing Cell Transplantation into the Brain of Two Amyotrophic Lateral Sclerosis (ALS) Patients. <i>Brain Pathology</i> , 2010, 20, 730-737.	4.1	25
89	C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian population. <i>Journal of Neurology</i> , 2015, 262, 2498-2503.	3.6	25
90	Common polymorphisms of chemokine (CX3C motif) receptor 1 gene modify amyotrophic lateral sclerosis outcome: A population-based study. <i>Muscle and Nerve</i> , 2018, 57, 212-216.	2.2	25

#	ARTICLE	IF	CITATIONS
91	Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. <i>Journal of Neurology</i> , 2019, 266, 1633-1642.	3.6	25
92	Religiousness is positively associated with quality of life of ALS caregivers. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 168-171.	2.1	24
93	A20 in Multiple Sclerosis and Parkinson's Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?. <i>Neurotoxicity Research</i> , 2017, 32, 1-7.	2.7	23
94	C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten. <i>Human Molecular Genetics</i> , 2017, 26, 1133-1145.	2.9	23
95	Mutational Analysis of Known ALS Genes in an Italian Population-Based Cohort. <i>Neurology</i> , 2021, 96, e600-e609.	1.1	23
96	Characteristics and influence on quality of life of new-onset pain in critical COVID-19 survivors. <i>European Journal of Pain</i> , 2022, 26, 680-694.	2.8	23
97	Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. <i>Brain</i> , 2022, 145, 276-284.	7.6	22
98	A de novo nonsense mutation of the FUS gene in an apparently familial amyotrophic lateral sclerosis case. <i>Neurobiology of Aging</i> , 2014, 35, 1513.e7-1513.e11.	3.1	21
99	ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. <i>Neurobiology of Aging</i> , 2015, 36, 2906.e1-2906.e5.	3.1	19
100	Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort. <i>Journal of Neurology</i> , 2017, 264, 2224-2231.	3.6	19
101	Multicenter validation of [¹⁸ F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 570-577.	1.7	19
102	Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. <i>Molecular Neurodegeneration</i> , 2021, 16, 52.	10.8	19
103	Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. <i>The Lancet Digital Health</i> , 2022, 4, e359-e369.	12.3	19
104	The rare G93D mutation causes a slowly progressing lower motor neuron disease. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2008, 9, 35-39.	2.1	18
105	Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1117-1131.	6.4	18
106	Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 291-297.	1.9	18
107	Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2020, 267, 1615-1621.	3.6	18
108	Reduced cellular Ca ²⁺ availability enhances TDP-43 cleavage by apoptotic caspases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 725-734.	4.1	17

#	ARTICLE	IF	CITATIONS
109	Validation of the revised classification of cognitive and behavioural impairment in ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 734-739.	1.9	17
110	Differential Neuropsychological Profile of Patients With Amyotrophic Lateral Sclerosis With and Without <i>C9orf72</i> Mutation. <i>Neurology</i> , 2021, 96, e141-e152.	1.1	17
111	Analysis of the <i>KIFAP3</i> gene in amyotrophic lateral sclerosis: a multicenter survival study. <i>Neurobiology of Aging</i> , 2014, 35, 2420.e13-2420.e14.	3.1	16
112	Amyotrophic Lateral Sclerosis Incidence and Previous Prescriptions of Drugs for the Nervous System. <i>Neuroepidemiology</i> , 2016, 47, 59-66.	2.3	16
113	Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2019, 9, 5931.	3.3	16
114	The interplay among education, brain metabolism, and cognitive impairment suggests a role of cognitive reserve in Amyotrophic Lateral Sclerosis. <i>Neurobiology of Aging</i> , 2021, 98, 205-213.	3.1	15
115	Amyotrophic lateral sclerosis caregiver burden and patients' quality of life during COVID-19 pandemic. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 146-148.	1.7	15
116	Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia. <i>Journal of Neurology</i> , 2015, 262, 2662-2667.	3.6	14
117	Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1001-1003.	1.9	14
118	Metabolic brain changes across different levels of cognitive impairment in ALS: a ¹⁸ F-FDG-PET study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 357-363.	1.9	14
119	<i>SCFD1</i> expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. <i>Brain Communications</i> , 2021, 3, fcab236.	3.3	14
120	Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectiology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2016, 52, 841-854.	2.2	14
121	The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitoring. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 999-1000.	1.9	13
122	Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia. <i>Brain</i> , 2021, 144, 3710-3726.	7.6	13
123	Exploiting mutual information for the imputation of static and dynamic mixed-type clinical data with an adaptive k-nearest neighbours approach. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 174.	3.0	12
124	A familial ALS case carrying a novel p.G147C <i>SOD1</i> heterozygous missense mutation with non-executive cognitive impairment: Figure 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1437-1439.	1.9	11
125	Rationale and study design of an early care, therapeutic education, and psychological intervention program for the management of post-intensive care syndrome and chronic pain after COVID-19 infection (PAIN-COVID): study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 486.	1.6	11
126	Brain metabolic changes across King's stages in amyotrophic lateral sclerosis: a ¹⁸ F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1124-1133.	6.4	10

#	ARTICLE	IF	CITATIONS
127	Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18Fâ€¦FDGâ€¦positron emission tomography stud. <i>European Journal of Neurology</i> , 2021, 28, 745-753.	3.3	10
128	Italian adaptation of the Beaumont Behavioral Inventory (BBI): psychometric properties and clinical usability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 81-86.	1.7	10
129	Developments in the assessment of non-motor disease progression in amyotrophic lateral sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1419-1440.	2.8	10
130	The diagnostic value of the Italian version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 527-531.	1.7	10
131	Validation of the Italian version of self-administered ALSFRS-R scale. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 151-153.	1.7	9
132	Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2242-2250.	6.4	9
133	Conjugal amyotrophic lateral sclerosis: suggestion for the implication of environmental factors. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2001, 2, 165-166.	1.2	8
134	Plasma amino acids patterns and age of onset of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 371-375.	1.7	8
135	HFE p.H63D polymorphism does not influence ALS phenotype and survival. <i>Neurobiology of Aging</i> , 2015, 36, 2906.e7-2906.e11.	3.1	8
136	The transcription factor Nurr1 is up-regulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	2.4	8
137	What is amyotrophic lateral sclerosis prevalence?. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 203-208.	1.7	8
138	Arterial blood gas analysis: base excess and carbonate are predictive of noninvasive ventilation adaptation and survival in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 33-39.	1.7	8
139	Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates. <i>Liver International</i> , 2022, 42, 435-443.	3.9	8
140	Social cognition deficits in amyotrophic lateral sclerosis: A pilot crossâ€¦sectional populationâ€¦based study. <i>European Journal of Neurology</i> , 2022, 29, 2211-2219.	3.3	8
141	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. <i>Neuron</i> , 2011, 69, 397.	8.1	7
142	Replication of association of CHRNA4 rare variants with sporadic amyotrophic lateral sclerosis: The Italian multicentre study. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 580-584.	2.1	7
143	Analysis of the GCG repeat length in NIPA1 gene in C9orf72-mediated ALS in a large Italian ALS cohort. <i>Neurological Sciences</i> , 2019, 40, 2537-2540.	1.9	7
144	Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis. <i>NeuroImage: Clinical</i> , 2020, 27, 102312.	2.7	7

#	ARTICLE	IF	CITATIONS
145	G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial). <i>BMJ Open</i> , 2020, 10, e034049.	1.9	7
146	The heterozygous deletion c.1509_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with cognitive impairment. <i>Neurobiology of Aging</i> , 2021, 103, 130.e1-130.e7.	3.1	7
147	Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2022, 12, 395.	3.3	7
148	Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression. <i>Journal of Neurology</i> , 2022, 269, 3858-3878.	3.6	7
149	Monomelic amyotrophy is not always benign: A case report. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 307-308.	2.1	6
150	A novel p.E121G heterozygous missense mutation of SOD1 in an apparently sporadic ALS case with a 14-year course. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 127-128.	1.7	6
151	ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion. <i>Neurobiology of Aging</i> , 2016, 39, 218.e5-218.e8.	3.1	6
152	Amyotrophic lateral sclerosis onset after prolonged treatment with a VEGF receptors inhibitor. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 129-130.	1.7	5
153	Curable or treatable? The implications of different definitions of illness when treating patients suffering from amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 15-20.	1.7	5
154	Acoustic reflex patterns in amyotrophic lateral sclerosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 679-683.	1.6	5
155	Neck flexor weakness at diagnosis predicts respiratory impairment in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 1181-1187.	3.3	4
156	Do ecological factors influence the clinical presentation of amyotrophic lateral sclerosis?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1017-1019.	1.9	4
157	Local infiltration analgesia for total knee arthroplasty: Does a mixture of ropivacaine and epinephrine have an impact on hemodynamics? An observational cohort study. <i>Saudi Journal of Anaesthesia</i> , 2020, 14, 335.	0.7	4
158	Brain ^{18F} fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis with TARDBP mutations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1021-1023.	1.9	4
159	Prospective epidemiological registers: a valuable tool for uncovering ALS pathogenesis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1066-1066.	1.9	3
160	An ALS case with a novel D90N-SOD1 heterozygous missense mutation. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 393-395.	2.1	3
161	Persistent idiopathic hypoglossal nerve palsy: A motor neuron disease-mimic syndrome?. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 274-276.	1.7	3
162	A novel p.Ser108LeufsTer15 SOD1 mutation leading to the formation of a premature stop codon in an apparently sporadic ALS patient: insights into the underlying pathomechanisms. <i>Neurobiology of Aging</i> , 2018, 72, 189.e11-189.e17.	3.1	3

#	ARTICLE	IF	CITATIONS
163	A familial amyotrophic lateral sclerosis pedigree discordant for a novel p.Glu46Asp heterozygous OPTN variant and the p.Ala5Val heterozygous SOD1 missense mutation. <i>Journal of Clinical Neuroscience</i> , 2020, 75, 223-225.	1.5	3
164	Broadening the clinical spectrum of FUS mutations: a case with monomelic amyotrophy with a late progression to amyotrophic lateral sclerosis. <i>Neurological Sciences</i> , 2021, 42, 1207-1209.	1.9	3
165	GBA variants influence cognitive status in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, , jnnp-2021-327426.	1.9	3
166	Endogenous Cognitive Tasks for Brain-Computer Interface: A Mini-Review and a New Proposal. , 2021, , .		3
167	Causal associations of genetic factors with clinical progression in amyotrophic lateral sclerosis. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 216, 106681.	4.7	3
168	A novel splice site FUS mutation in a familial ALS case: effects on protein expression. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, , 1-9.	1.7	2
169	Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 424-429.	1.7	2
170	Tailoring patientsâ€™ enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 108-115.	1.7	1
171	Can amyotrophic lateral sclerosis progression really pause? A cohort study using the medical research council scale. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, , 1-7.	1.7	1
172	Sclerosi laterale amiotrofica come modello di gestione interdisciplinare. <i>Salute E Societa</i> , 2015, , 173-184.	0.1	1
173	Acute, Hemorrhagic, Necrotizing Pancreatitis Associated With Riluzole Treatment in a Patient With Amyotrophic Lateral Sclerosis. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, .	0.9	1
174	Comorbidity of Cervical Spondylogenic Myelopathy and Amyotrophic Lateral Sclerosis: When Electromyography Makes the Difference in Diagnosis. <i>European Neurology</i> , 2020, 83, 626-629.	1.4	1
175	Amyotrophic lateral sclerosis mimic syndrome due to a dorsal spinal cord neurofibroma. <i>Neurological Sciences</i> , 2010, 31, 111-113.	1.9	0
176	Stapedial Reflex: A Possible Novel Biomarker of Early Bulbar Involvement in Amyotrophic Lateral Sclerosis Patients. <i>Audiology and Neuro-Otology</i> , 2021, 26, 353-360.	1.3	0
177	Nature meets nurture in amyotrophic lateral sclerosis. <i>Lancet Neurology</i> , The, 2021, 20, 332-333.	10.2	0